impact
respiratori
syncyti
viru
rsv
global
health
becom
increasingli
appreci
advanc
rsv
diagnost
method
increas
avail
rapid
sensit
specif
diagnost
test
well
enhanc
understand
molecular
structur
function
viru
acceler
understand
rsv
biolog
epidemiolog
past
decad
seriou
rsv
diseas
infant
elderli
immunocompromis
host
well
recogn
develop
potenti
rsv
prevent
measur
underway
although
rsv
vaccin
current
avail
prevent
rsv
world
health
organ
estim
rsv
vaccin
clinic
use
within
next
year
mani
strategi
prevent
rsv
infant
children
adult
consider
potenti
matern
immun
prevent
seriou
diseas
infant
discuss
chapter
respiratori
syncyti
viru
primari
caus
viral
lower
respiratori
tract
infect
lrti
infant
worldwid
rsv
associ
high
rate
hospit
particularli
infant
less
month
c
h
p
e
r
age
estim
global
burden
million
infect
death
annual
children
five
unit
state
us
mani
industri
countri
rsv
common
infect
result
hospit
admiss
among
infant
temper
climat
rsv
produc
annual
midwint
epidem
clinic
character
bronchiol
infant
rsv
outbreak
less
clearli
delin
tropic
area
yearround
infect
may
occur
without
epidem
estim
death
due
rsv
children
occur
resourcelimit
set
make
prevent
rsvassoci
mortal
region
world
limit
access
health
care
high
prioriti
clinic
manifest
rsv
infect
young
children
includ
nasal
congest
difficulti
breath
potenti
result
respiratori
distress
bronchiol
pneumonia
without
fever
well
apnea
young
infant
rsv
associ
ill
common
children
less
year
age
moder
sever
diseas
seen
primarili
infant
rsv
diseas
infant
month
age
account
half
document
rsv
case
mani
studi
vast
major
rsvrelat
hospit
occur
young
children
first
two
year
life
one
prospect
cohort
studi
arizona
us
almost
infant
medic
attend
ill
first
year
life
due
rsv
usual
diagnos
bronchiol
pneumonia
similar
rate
observ
develop
countri
least
us
infant
hospit
rsv
diseas
peak
occurr
second
month
life
hospit
rate
higher
risk
group
includ
prematur
infant
underli
cardiac
pulmonari
diseas
infant
aborigin
popul
nativ
american
alaska
nativ
may
hospit
rate
time
higher
gener
us
popul
date
rsv
treatment
mainli
support
consist
respiratori
support
fluid
manag
support
treat
apnea
associ
rsv
infect
preterm
young
infant
may
also
requir
despit
rel
minim
care
typic
administ
rsvinfect
children
industri
countri
rsvrelat
mortal
substanti
higher
low
middl
incom
countri
rsv
common
caus
symptomat
respiratori
ill
healthi
adult
popul
year
age
compar
influenza
rsv
infect
symptom
gener
appear
last
longer
less
fever
us
studi
adult
rsv
lower
respiratori
tract
symptom
defin
tracheobronch
bronchiti
wheez
recent
studi
pneumonia
hospit
patient
age
year
rsv
respons
case
pneumonia
per
individu
increas
hospit
rate
associ
increas
age
howev
rate
sever
rsv
infect
rsv
pneumonia
pregnant
women
remain
poorli
character
reflect
major
gap
rsv
epidemiolog
studi
rsv
infect
diseas
pregnanc
base
case
report
secondari
analys
influenza
vaccin
trial
recent
prospect
longitudin
commun
base
studi
conduct
houston
texa
provid
addit
inform
regard
epidemiolog
rsv
respiratori
virus
healthi
pregnant
women
receiv
prenat
care
commun
obstetr
clinic
studi
evalu
symptomat
asymptomat
women
obstetr
popul
reflect
contemporari
makeup
pregnant
women
us
median
age
year
broad
represent
racial
ethnic
background
signific
find
houston
studi
onethird
women
acut
respiratori
symptom
diseas
consist
lrti
author
defin
difficulti
breath
short
breath
wheez
cyanosi
morbid
associ
multipl
respiratori
virus
includ
rsv
consider
symptom
note
virus
common
virus
detect
studi
includ
rhinoviru
coronaviru
rsv
overal
attack
rate
rsv
among
ambulatori
pregnant
women
popul
base
laboratoryconfirm
rsv
infect
document
polymeras
chain
reaction
pcr
test
respiratori
secret
serolog
diagnosi
ad
data
influenza
vaccin
trial
commonli
use
determin
incid
rsv
respiratori
virus
order
estim
rsv
epidemiolog
pregnant
women
approach
permit
evalu
mani
pregnant
women
prospect
studi
potenti
issu
main
limit
use
influenzalikeil
ili
criteria
requir
presenc
fever
guid
sampl
obtain
diagnosi
respiratori
ill
also
surveil
often
ongo
influenza
season
ili
criteria
typic
base
combin
fever
cough
andor
sore
throat
major
case
rsv
adult
afebril
addit
influenza
rsv
season
may
overlap
like
lead
underestim
rsv
burden
sampl
perform
period
influenza
viru
circul
two
larg
matern
influenza
vaccin
studi
sponsor
bill
melinda
gate
foundat
evalu
incid
matern
respiratori
diseas
due
rsv
pregnanc
nepal
nasal
swab
collect
prospect
women
fever
respiratori
symptom
year
round
rsv
preval
incid
personyear
overal
south
africa
rsv
preval
matern
influenza
trial
specimen
obtain
base
presenc
respiratori
symptom
much
higher
incid
case
per
personyear
overal
importantli
matern
rsv
case
south
africa
trial
fever
document
rsv
associ
increas
risk
low
birth
weight
preterm
birth
either
south
african
nepal
studi
although
number
rsvinfect
women
studi
small
recent
pregnanc
influenza
vaccin
effect
network
prevent
us
center
diseas
control
prevent
site
four
countri
evalu
impact
rsv
hospit
among
pregnant
women
high
incom
countri
us
canada
israel
australia
among
total
popul
pregnant
women
hospit
variou
season
least
one
hospit
associ
diagnosi
acut
respiratori
febril
ill
admit
test
virus
includ
rsv
highlight
low
level
awar
test
rsv
obstetr
provid
importantli
rang
rsvposit
case
total
women
test
posit
rsv
pcr
twothird
test
diagnos
rsv
occur
third
trimest
pregnanc
preexist
health
condit
document
women
asthma
common
importantli
diagnosi
pneumonia
frequent
among
rsvposit
compar
rsv
neg
women
vs
p
nearli
half
rsvposit
women
requir
admiss
day
signific
associ
document
admiss
rsv
confirm
infect
subsequ
preterm
birth
occur
rsvposit
women
compar
rsvneg
women
p
howev
differ
frequenc
overal
low
birth
weight
smallforgest
age
infant
rsvposit
neg
women
studi
suggest
rsv
import
caus
lrti
hospit
pregnant
women
particularli
underli
medic
condit
howev
given
small
proport
pregnant
women
test
rsv
hospit
admiss
acut
respiratori
ill
data
requir
fulli
appreci
burden
popul
rsv
first
identifi
chanock
identifi
pathogen
young
infant
sever
year
later
reason
diseas
predilect
young
children
studi
sinc
time
impact
matern
antibodi
subsequ
develop
rsv
diseas
young
children
investig
year
origin
concern
potenti
augment
rsv
diseas
presenc
maternallyderiv
antibodi
young
infant
consid
possibl
subsequ
studi
util
differ
studi
design
laboratori
analysi
rsvspecif
antibodi
dispel
theori
actual
demonstr
infant
rsv
diseas
concentr
rsvspecif
antibodi
compar
infant
diseas
landmark
studi
conduct
glezen
et
al
houston
texa
rsvspecif
serum
neutral
antibodi
shown
effici
transfer
mother
newborn
high
level
neutral
antibodi
acquir
transplacent
neonat
protect
infant
lrti
first
month
life
later
studi
denmark
calcul
reduct
hospit
first
month
life
everi
twofold
increas
cord
blood
neutral
antibodi
effici
transplacent
transfer
matern
rsv
antibodi
demonstr
multipl
studi
industri
countri
well
africa
asia
healthi
fullterm
maternalcord
blood
pair
matern
cord
rsvspecif
antibodi
ratio
studi
demonstr
antibodi
infant
mother
transplacent
transfer
ratio
vaccin
nonvaccin
women
approxim
declin
virusspecif
immun
provid
matern
rsv
antibodi
close
mirror
halflif
immunoglobulin
approxim
day
princip
igg
subclass
antibodi
rsv
transplacent
transfer
preterm
term
neonat
current
human
anim
data
mice
cotton
rat
lamb
calv
nonhuman
primat
support
serum
neutral
antibodi
good
correl
immun
rsv
diseas
lower
respiratori
tract
necessarili
upper
respiratori
tract
standard
rsv
neutral
assay
work
toward
develop
intern
standard
underway
rsv
member
genu
pneumoviru
one
two
paramixovirus
group
human
metapneumoviru
two
antigen
distinct
subgroup
rsva
rsvb
rsv
neg
sens
nonseg
rna
genom
encod
protein
tabl
two
glycoprotein
virion
membran
fusion
f
attach
bind
g
protein
carri
antigen
determin
elicit
neutral
antibodi
rsv
tabl
immun
rsv
reli
primarili
develop
neutral
antibodi
surfac
protein
nonneutr
antibodi
f
g
small
hydrophob
sh
surfac
protein
inhibit
infect
complement
mediat
neutral
antibodi
depend
cell
mediat
toxic
viral
antigen
induc
protect
cell
mediat
immun
given
fprotein
play
critic
role
viral
entri
host
cell
highli
conserv
within
rsva
rsvb
subtyp
prefer
target
rsv
vaccin
monoclon
antibodi
fprotein
contain
antigen
site
elicit
product
high
potenc
neutral
antibodi
rsv
fprotein
present
two
structur
conform
prefus
pref
postfus
postf
form
cours
infect
host
cell
antibodi
direct
antigen
site
present
pref
conform
effici
neutral
rsv
direct
antigen
site
present
stabl
postf
confirm
although
contain
central
conserv
domain
avail
neutral
antibodi
bind
gprotein
primari
target
vaccin
develop
mostli
cover
glycan
well
conserv
within
rsv
type
fprotein
earli
studi
target
antibodi
prophylaxi
prevent
rsv
infect
highrisk
infant
util
hightit
human
immunoglobulin
product
obtain
screen
volunt
administ
infant
intraven
one
studi
highrisk
children
administ
monthli
dose
intraven
immunoglobulin
contain
high
level
rsv
neutral
antibodi
rsvivig
reduc
rate
hospit
rsv
infect
human
immunoglobulin
product
respigam
medimmun
gaithersburg
md
licens
subsequ
human
monoclon
antibodi
specif
fprotein
rsv
palivizumab
synagi
medimmun
astrazeneca
cambridg
uk
evalu
approv
us
food
drug
administr
fda
use
intramuscular
inject
highrisk
children
studi
definit
demonstr
rsvspecif
antibodi
alon
may
prevent
reduc
rsv
diseas
infant
current
palivizumab
fdaand
european
medicin
agencyapprov
therapi
util
prophylaxi
rsv
infant
young
children
increas
risk
hospit
palivizumab
origin
approv
preterm
infant
week
gestat
age
infant
chronic
lung
diseas
prematur
hemodynam
signific
congenit
heart
diseas
prevent
approach
requir
intramuscular
administr
mgkg
palivizumab
interv
rsv
season
shown
safe
effect
prevent
seriou
rsv
ill
hospit
highrisk
young
children
refin
recommend
palivizumab
prophylaxi
chang
past
decad
due
part
consider
cost
effect
impact
restrict
polici
palivizumab
use
us
limit
use
among
preterm
infant
less
week
gestat
birth
describ
increas
case
rsv
hospit
morbid
young
infant
week
gestat
report
studi
surveil
system
place
studi
includ
birth
cohort
inform
polici
use
palivizumab
prevent
sever
rsv
highrisk
infant
us
specif
recommend
pediatr
popul
receiv
palivizumab
therapi
current
vari
countri
major
advanc
understand
structur
function
highli
conserv
rsv
fprotein
target
antibodi
current
vaccin
candid
made
centuri
exampl
known
activ
rsv
fprotein
prefus
state
postfus
state
requir
structur
chang
conform
chang
expos
variou
antigen
site
elicit
product
neutral
antibodi
vari
potenc
depend
site
rsv
fprotein
crystal
prefus
form
stabil
substanti
proport
neutral
antibodi
respons
rsv
shown
direct
prefus
conform
f
protein
pref
antibodi
postul
serv
accur
correl
protect
allow
identif
novel
antigen
site
may
serv
potenti
antigen
monoclon
antibodi
vaccin
develop
next
gener
rsv
fprotein
monoclon
antibodi
target
antigen
site
prefus
protein
enhanc
neutral
activ
activ
studi
motavizumab
medimmun
deriv
palivizumab
higher
affin
longer
halflif
effect
reduc
rsv
hospit
highrisk
fullterm
infant
us
licens
due
safeti
concern
allerg
reaction
anoth
monoclon
antibodi
product
suptavumab
regeneron
pharmaceut
tarrytown
ny
fail
meet
primari
outcom
prevent
medic
attend
rsv
infect
preterm
infant
born
week
gestat
phase
iii
infant
clinic
trial
http
investorregeneroncomreleasedetailcfm
novel
investig
monoclon
antibodi
medimmun
aztrazeneca
llc
recombin
human
immunoglobulin
monoclon
antibodi
target
prefus
conform
rsv
fprotein
monoclon
antibodi
bind
highli
conserv
epitop
rsv
f
neutral
divers
group
rsv
b
strain
higher
activ
palivizumab
extend
halflif
compar
palivizumab
due
mutat
fcdomain
yte
antibodi
studi
safeti
toler
pharmacokinet
adult
healthi
preterm
infant
current
undergo
clinic
efficaci
studi
preterm
young
infant
qualifi
palivizumab
us
clinic
trial
gov
id
us
fda
grant
breakthrough
therapi
design
product
februari
indic
product
receiv
expedit
develop
regulatori
review
websit
access
may
wwwastrazeneca
iii
futur
vaccin
use
pregnanc
develop
vaccin
prevent
rsv
ongo
sinc
initi
isol
infant
sever
lrti
first
vaccin
evalu
clinic
trial
infant
formalininactiv
vaccin
result
inadequ
neutral
antibodi
respons
augment
diseas
subsequ
wildtyp
infect
vaccin
recipi
experi
led
care
consider
potenti
strategi
rsv
prevent
develop
variou
rsv
vaccin
candid
current
undergo
evalu
includ
live
attenu
chimer
vaccin
subunit
vaccin
particl
base
vaccin
includ
viruslik
particl
nanoparticl
nucleic
acid
recombin
vector
vaccin
vaccin
yet
licens
prevent
rsv
vaccin
candid
variou
phase
preclin
clinic
develop
target
specif
popul
risk
includ
infant
young
children
elderli
pregnant
women
would
receiv
vaccin
protect
newborn
sever
rsv
diseas
tabl
http
wwwpathorg
resourcesrsvvaccineandmabsnapshot
vaccin
specif
tailor
popul
necessari
establish
effect
multiprong
approach
reduc
burden
rsv
particularli
young
children
exampl
live
attenu
rsv
vaccin
may
administ
directli
nasal
mucosa
young
children
induc
robust
local
system
immun
respons
given
respons
vaccin
month
age
may
limit
interfer
matern
antibodi
overal
lower
immunogen
requir
repeat
dose
vaccin
last
protect
achiev
particular
challeng
infant
low
rsv
antibodi
concentr
greater
risk
acquir
infect
earlier
life
natur
rsv
infect
confer
long
last
immun
therefor
reinfect
childhood
life
common
furthermor
highest
morbid
mortal
rsv
healthi
term
infant
underli
condit
increas
risk
complic
prematur
cardiopulmonari
diseas
occur
first
month
life
earli
activ
immun
effect
consequ
passiv
antibodi
administr
major
strategi
rsv
prevent
highrisk
infant
howev
passiv
immun
limit
need
restrict
costli
intervent
group
highest
risk
leav
major
infant
born
term
suscept
rsv
infect
complic
iii
futur
vaccin
use
pregnanc
matern
vaccin
appear
direct
optim
strategi
prevent
earli
rsv
diseas
neonat
young
infant
strategi
support
follow
observ
matern
rsv
infect
prior
deliveri
correl
decreas
incid
rsv
bronchiol
infant
higher
concentr
rsvspecif
maternallyderiv
antibodi
birth
associ
lower
incid
later
onset
rsv
diseas
neonat
first
month
life
passiv
antif
igg
eg
palivizumab
administr
reduc
incid
sever
rsv
diseas
pregnant
women
prime
rsv
previou
infect
vaccin
boost
antibodi
achiev
higher
concentr
time
activ
antibodi
transfer
mechan
placenta
favor
passag
antibodi
fetu
transplacent
transfer
rsvspecif
igg
mother
neonat
highli
effici
addit
transplacent
antibodi
transfer
also
potenti
protect
lactat
infant
rsvspecif
breastmilk
antibodi
natur
vaccin
induc
preced
success
matern
immun
strategi
prevent
matern
infant
tetanu
pertussi
influenza
goal
matern
immun
program
prevent
rsv
infant
includ
prevent
infant
death
hospit
prevent
andor
reduct
sever
rsv
lrti
delay
onset
first
episod
rsv
infect
delay
onset
import
given
infant
may
capabl
resist
overcom
initi
rsv
ill
occur
later
first
even
second
year
life
indirect
benefit
breastmilk
antibodi
prolong
durat
protect
transplacent
deriv
antibodi
reduct
household
transmiss
infect
matern
infant
protect
document
protect
mother
pregnanc
obstetr
ill
complic
associ
rsv
infect
third
trimest
gestat
may
addit
potenti
benefit
ideal
rsv
vaccin
matern
immun
one
live
viru
vaccin
administ
singl
dose
pregnanc
prefer
second
earli
third
trimest
gestat
allow
suffici
time
transplacent
antibodi
transfer
safe
mother
infant
abl
induc
protect
antibodi
effici
transfer
infant
via
placenta
achiev
high
concentr
neutral
antibodi
protect
infant
long
enough
first
month
iii
futur
vaccin
use
pregnanc
life
natur
decay
passiv
acquir
matern
antibodi
allow
highest
protect
infant
first
month
life
declin
afterward
therefor
matern
immun
like
need
follow
activ
infant
immun
start
earli
second
month
birth
reduc
impact
rsv
first
year
life
strategi
matern
follow
infant
immun
would
effect
infant
born
term
passiv
antibodi
administr
might
option
infant
vaccin
mother
receiv
activ
immun
would
less
like
acquir
rsv
infect
first
month
life
period
greatest
vulner
experi
acquir
infect
modifi
render
less
sever
presenc
matern
deriv
vaccin
induc
antibodi
matern
immun
like
effect
method
prevent
earli
diseas
among
prematur
infant
would
benefit
suffici
durat
gestat
achiev
optim
transplacent
transfer
high
antibodi
concentr
birth
therefor
administr
passiv
rsv
antibodi
eg
palivizumab
follow
activ
infant
immun
would
adequ
strategi
prevent
rsv
preterm
infant
durat
protect
maternallyderiv
antibodi
infant
limit
concentr
antibodi
present
birth
rel
short
antibodi
halflif
result
rapid
natur
antibodi
decay
first
month
life
therefor
passiv
activ
immun
import
role
prevent
rsv
infant
even
routin
matern
immun
administr
monoclon
antibodi
birth
becom
avail
one
remain
challeng
develop
rsv
vaccin
lack
known
serolog
correl
protect
evalu
vaccin
efficaci
effect
correl
protect
identifi
larg
clinic
trial
requir
assess
efficaci
candid
rsv
vaccin
matern
infant
immun
anoth
import
area
research
field
rsv
address
need
better
understand
mechan
protect
beyond
antibodi
innat
cellular
immun
definit
progress
design
develop
rsv
vaccin
driven
better
understand
conform
depend
immunogen
fprotein
need
target
neutral
sensit
epitop
function
form
fprotein
rsv
vaccin
matern
immun
develop
date
base
fprotein
rsv
current
four
vaccin
develop
matern
immun
two
phase
clinic
trial
one
phase
ii
iii
clinic
trial
tabl
nonadjuv
purifi
fprotein
vaccin
rsv
first
vaccin
evalu
pregnanc
nearli
year
ago
earli
small
proof
concept
random
placebocontrol
studi
healthi
women
vaccin
week
gestat
rsv
vaccin
well
toler
though
significantli
increas
neutral
antibodi
titer
rsv
develop
nevertheless
matern
immun
experiment
vaccin
safe
mother
infant
obstetr
advers
event
associ
vaccin
effici
transplacent
passag
vaccin
induc
antibodi
demonstr
halflif
antibodi
estim
day
antif
iga
igg
present
breastmilk
vaccin
recipi
higher
concentr
placebo
recipi
first
month
deliveri
importantli
close
follow
infant
natur
infect
two
consecut
viral
season
enhanc
rsv
diseas
observ
purifi
recombin
pref
protein
vaccin
prepar
chines
hamster
ovari
cell
glaxosmithklin
gsk
investig
vaccin
evalu
approxim
nonpregn
women
assess
reactogen
immunogen
variou
dosag
adjuv
nonadjuv
formul
formul
vaccin
boost
preexist
antibodi
year
old
women
compar
immunogen
safeti
profil
similar
tetanu
diphtheria
pertussi
tdap
vaccin
administ
routin
pregnanc
us
variou
countri
vaccin
construct
plan
evalu
pregnant
women
global
phase
iii
studi
expect
begin
lastli
aluminumadjuv
rsv
fprotein
nanoparticl
vaccin
novavax
inc
gaithersburg
maryland
us
evalu
women
childbear
age
phase
ii
studi
pregnant
women
prior
first
vaccin
evalu
phase
iii
clinic
trial
seek
indic
administr
pregnanc
phase
ii
studi
demonstr
vaccin
safe
well
toler
induc
significantli
higher
concentr
anti
figg
also
neutral
antibodi
palivizumab
compet
antibodi
studi
also
found
matern
antibodi
respons
peak
day
vaccin
interv
day
matern
vaccin
deliveri
maxim
transplacent
antibodi
transfer
measur
antibodi
studi
allow
progress
global
phase
iii
efficaci
clinic
trial
evalu
matern
vaccin
protect
rsv
infant
clinic
trial
healthi
pregnant
women
conduct
countri
worldwid
primari
object
studi
determin
efficaci
matern
immun
medic
signific
rsv
lrti
infant
variou
time
point
includ
first
day
life
day
mother
vaccin
singl
dose
vaccin
week
gestat
clinic
definit
medic
signific
rsv
lrti
includ
presenc
least
two
clinic
symptom
ill
laboratori
confirm
rsv
infect
pcr
object
assess
tachypnea
hypoxemia
satur
secondari
endpoint
iii
futur
vaccin
use
pregnanc
includ
reduct
rsv
lrti
hospit
rsv
lrti
sever
hypoxemia
satur
preliminari
data
share
date
manufactur
indic
among
women
random
receiv
vaccin
placebo
vaccin
well
toler
associ
vaccinerel
matern
infant
obstetr
advers
event
studi
fail
meet
primari
object
efficaci
medic
signific
rsv
lrti
infant
estim
ci
day
life
secondari
outcom
rsv
lrti
sever
hypoxemia
also
met
howev
matern
vaccin
effect
protect
infant
rsvassoci
lrti
hospit
first
day
day
birth
tabl
http
irnovavaxcomnewsreleas
vaccin
licensur
base
studi
unlik
us
given
observ
geograph
variabl
vaccin
efficaci
overal
lower
number
case
expect
result
encourag
prespecifi
analys
conduct
evalu
result
util
expand
data
increas
number
evalu
subject
vaccin
efficaci
achiev
first
day
life
vari
nearli
primari
secondari
outcom
tabl
consid
result
worthi
continu
develop
evalu
vaccin
studi
pivot
gener
data
better
understand
potenti
matern
rsv
immun
prevent
sever
outcom
rsv
infant
answer
specif
programmat
question
impact
time
immun
pregnanc
interv
vaccin
deliveri
optim
impact
matern
immun
protect
infant
observ
geograph
season
potenti
popul
base
differ
vaccin
efficaci
occur
help
inform
design
futur
clinic
trial
result
studi
continu
evalu
experi
trial
provid
impetu
ongo
develop
evalu
rsv
vaccin
matern
immun
import
contribut
defin
clinic
endpoint
clinic
trial
power
experiment
vaccin
advanc
develop
potenti
administr
pregnanc
includ
aluminum
hydroxid
adjuv
rsv
stabil
prefus
f
subunit
vaccin
began
enrol
phase
iib
placebo
control
random
clinic
trial
pregnant
women
us
august
pfizer
http
clinicaltrialsgov
unadjuv
pref
subunit
vaccin
begin
phase
ii
evalu
pregnant
women
complet
dose
rang
immunogen
safeti
evalu
nonpregn
healthi
women
gsk
biolog
http
tabl
parallel
research
field
activ
establish
standard
method
assess
rsv
infect
immun
clinic
assess
sever
diseas
determin
correl
protect
rsv
prefer
product
characterist
rsv
vaccin
develop
clear
road
map
research
develop
technolog
associ
rsv
vaccin
place
variou
vaccin
candid
remain
preclin
clinic
phase
develop
work
identifi
key
necessari
element
implement
matern
rsv
vaccin
worldwid
continu
support
multipl
stakehold
implement
rsv
vaccin
matern
immun
guid
accur
estim
rsv
diseas
burden
infant
determin
potenti
impact
establish
robust
surveil
system
assess
vaccin
safeti
efficaci
outcom
implement
key
support
key
polici
maker
nation
local
matern
child
health
system
fund
administr
organ
fig
success
matern
immun
deliveri
platform
would
includ
integr
antenat
neonat
care
servic
immun
program
inform
exist
vaccin
eg
tetanu
influenza
routin
antenat
care
intervent
eg
hiv
diagnosi
prevent
would
like
need
strengthen
financi
polici
support
lastli
effect
commun
plan
advocaci
plan
import
element
ensur
vaccin
uptak
educ
provid
pregnant
women
parent
public
impact
rsv
role
matern
immun
prevent
infant
diseas
associ
mortal
global
burden
morbid
mortal
associ
rsv
diseas
infant
substanti
particularli
low
lowmiddl
incom
countri
matern
immun
feasibl
strategi
potenti
significantli
reduc
impact
rsv
diseas
young
infant
worldwid
vaccin
matern
immun
activ
preclin
clinic
develop
encourag
result
ongo
research
implement
plan
activ
support
concept
rsv
prevent
matern
immun
possibl
achiev
tangibl
progress
control
rsv
diseas
young
infant
near
futur
